Stomach Cancer Treatment Market Size, Share & Industry Analysis, By Drug Type (Programmed Cell Death Protein 1 (PD-1) Inhibitors, Human Epidermal Growth Factor Receptor (HER2) Antagonists, and Others), By Disease Indication (Gastric Adenocarcinoma, Gastrointestinal Stromal Tumor (GIST)), By Route of Administration (Oral and Parenteral) By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others) and Regional Forecast, 2025-2032

Last Updated: November 17, 2025 | Format: PDF | Report ID: FBI102094

To get information on various segments, share your queries with us

ATTRIBUTE	DETAILS
Study Period	2019-2032
Base Year	2024
Estimated Year	2025
Forecast Period	2024-2032
Historical Period	2019-2023
Unit	Value (USD million)
Segmentation	By Drug Type Programmed Cell Death Protein 1 (PD-1) Inhibitors Human Epidermal Growth Factor Receptor (HER2) Antagonists Vascular Endothelial Growth Factor Receptor (VEGFR) Antagonists Others
	By Disease Indication Gastric Adenocarcinoma Gastrointestinal Stromal Tumor (GIST) Gastric Neuroendocrine Tumors (gNET)
	By Route of Administration Oral Parenteral
	By Distribution Channel Hospital Pharmacy Retail Pharmacy Online Pharmacy
	By Geography North America (U.S. and Canada) Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe) Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia- Pacific) Latin America (Brazil, Mexico, and Rest of Latin America) Middle East and Africa ( South Africa, GCC, and Rest of Middle East & Africa)